Fintel reports that on May 28, 2025, Stifel downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from Buy to Hold.

Fintel reports that on May 27, 2025, HC Wainwright & Co. downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from ...

On Tuesday, Stifel analysts downgraded Vigil Neuroscience Inc (NASDAQ: VIGL) stock from a Buy to a Hold rating, concurrently reducing the price target from $11.00 to $8.00. This adjustment comes ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

One of Charleston's most architecturally distinguished private residences, the Chisolm-Alston House at 172 Tradd Street, has officially entered the market, marking an extraordinary opportunity to own ...